Prof. Dr. med. Daniel M. Aebersold - Strahlentherapie | Radioonkologie, Bern - Publikationen

Aebersold D.M., Hirsch H.H., Backenstoss V., Moroni C.: V-Ha-ras dependent expression of interleukin-3 mRNA in premalignant PB-3c mast cells correlates with the formation of tumors without interleukin-3 gene rearrangements. Exp Hematol 25:395-404 (1997).

Aebersold D.M., Beer K.T., Laissue J., Hug S., Kollar A., Greiner R.H., Djonov V.: Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx. Int J Radiat Oncol Biol Phys 48(1):17-25 (2000).

Aebersold D.M., Kollar A., Beer K.T., Laissue J., Greiner R.H., Djonov V.: Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer (Radiat Oncol Invest) 96:41-54 (2001).

Aebersold D.M., Burri P., Beer K.T., Laissue J., Djonov V., Greiner, R.H., Semenza G.L.: Expression of hypoxia-inducible factor-1: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61:2911-2916 (2001).

Lindel K., Beer K.T., Laissue J., Greiner R.H., Aebersold D.M.: Human papillomavirus positive squamous cell carcinoma of the oropharynx. Cancer 92:805-813 (2001).

Yung Y., Yao Z., Aebersold D.M., Hanoch T., Seger R.: Altered regulation of ERK1b by MEK1 and PTP-SL, and modified Elk1- phosphorylation by ERK1b are caused by abrogation of the regulatory C- terminal sequence of ERKs. J Biol Chem 276:35280-35289 (2001).

Aebersold D.M., Froehlich S.C., Jonczy M., Beer K.T., Laissue J., Greiner R.H., Djonov V.: Expression of transforming growth factor-, epidermal growth factor receptor and platelet-derived growth factors A and B in oropharyngeal cancers treated by curative radiation therapy. Radiotherapy Oncol 63: 275-283 (2002).

Aebersold D.M., Landt O., Berthou S., Gruber G., Beer K.T., Greiner R.H., Zimmer, Y.: Prevalence and clinical impact of MET Y1253D activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. Oncogene 22(52): 8519-23 (2003).

Aebersold D.M., Isaak B., Thalmann G., Behrensmeier F., Kolotas C., Kranzbühler H., Mini R., Greiner R.H.: Applicability and dosimetric impact of ultrasound-based preplanning in high dose rate brachytherapy of prostate cancer. Strahlenther Onkol 180(6):351-7 (2004)

Berthou S., Aebersold D.M., Schmidt L.S., Stroka D., Heigel C., Streit B., Stalder D., Gruber G., Liang C., Howlett A.R., Candinas D., Greiner R.H., Lipson K.E., Zimmer Y.: The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.
Oncogene 23(31):5387-93 (2004).

Pajic B., Pallas A., Aebersold D.M., Greiner R.H.: Prospective study about course of primary pterygia after exclusive treatment with Strontium-/Yttrium-90 Irradiation. Strahlenther Onkol 180(8):510-6 (2004)

Aebersold D.M., Shaul Y., Yung Y.,Yarom N., Yao Z., Hanoch T., Seger R.: ERK1c, a 42-kDa ERK with a unique mode of regulation by phosphorylation, dephosphorylation und ubiquitination. Mol Cell Biol 22:10000-15 (2004)

Vetterli D., Kemmerling L., Behrensmeier F., Thalmann S., Born E.J., Mini R., Greiner R.H., Aebersold D.M.: Daily organ tracking in intensity-modulated radiotherapy of prostate cancer using an electronic portal imaging device with a dose saving acquisition mode. Radiother Oncol 79(1):101-8 (2006)

Goldblum D, Ghadjar P, Curschmann J, Greiner R, Aebersold D. Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study. Radiat Oncol. 1;3:22 (2008).

Ghadjar P, Vock J, Vetterli D, Manser P, Bigler R, Tille J, Madlung A, Behrensmeier F, Mini R, Aebersold DM. Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking. Radiat Oncol. 20;3:35 (2008).

Ganapathipillai SS, Medová M, Aebersold DM, Manley PW, Berthou S, Streit B, Blank-liss W, Greiner RH, Rothen-Rutishauser B, Zimmer Y. Coupling of mutated Met variants to DNA repair via Abl and Rad51. Cancer Research15;68(14):5769-77 (2008)

Ghadjar P, Schreiber-Facklam H, Gräter R, Evers C, Simcock M, Geretschläger A, Blumstein NM, Zbären P, Zimmer Y, Wilkens L, Aebersold DM. Quantitative Analysis of Extracapsular Extension of Metastatic Lymph Nodes and Its Significance in Radiotherapy Planning in Head and Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2010 Mar 15; 76 (4): 1127-32. Epub 2009 Aug 3. 

Ghadjar P, Blank-Liss W, Simcock M, Hegyi I, Beer KT, Moch H, Aebersold DM, Zimmer Y. MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. Clin Exp Metastasis. 2009; 26(7):809-15. Epub 2009 Jul 29.

Aebersold DM. Potential and future strategies for radiotherapy in hepatocellular carcinoma. LIVER INT, 29(2): 145-6, 2009 Feb.

Bekkering GE, Rutjes AW, Vlassov VV, Aebersold DM, von Bremen K, Jüni P, Kleijnen J. The effectiveness and safety of proton radiation therapy for indications of the eye : a systematic review. Strahlenther Onkol. 185(4):211-21 (2009).

Ghadjar P, Matzinger O, Isaak B, Behrensmeier F, Stroux A, Rentsch CA, Thalmann GN, Aebersold DM. Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. Radiother Oncol. 91(2):237-42 (2009). Epub 2009 Jan 21.

Ghadjar P, Keller T, Rentsch CA, Isaak B, Behrensmeier F, Stroux A, Thalmann GN, Aebersold DM. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. Brachytherapy. 8(1):45-51 (2009). Epub 2008 Nov 26.

Ghadjar P, Gwerder N, Madlung A, Behrensmeier F, Thalmann GN, Mini R, Aebersold DM. Use of gold markers for setup in image-guided fractionated high-dose-rate brachytherapy as a monotherapy for prostate cancer. Strahlenther Onkol, 185(11): 731-5, 2009 Nov. Epub 2009 Nov 10.

Vastardis I, Pajic B, Greiner RH, Pajic-Eggspuehler B, Aebersold DM. Prospective study of exclusive strontium-/yttrium-90 beta-irradiation of primary and recurrent pterygia with no prior surgical excision. Clinical outcome of long-term follow-up. Strahlenther Onkol, 185(12): 808-14, 2009 Dec.

Ghadjar P, Joos D, Martinelli M, Hullin R, Zwahlen M, Lössl K, Carrel T, Aebersold DM, Mohacsi P. Tailored total lymphoid irradiation in heart transplant patients: 10-years experience of one center. Radiat Oncol, 16;5:3, 2010 Jan.

Ghadjar P, Schreiber-Facklam H, Gräter R, Evers C, Simcock M, Geretschläger A, Blumstein NM, Zbären P, Zimmer Y, Wilkens L, Aebersold DM (2010) Quantitative analysis of extracapsular extension of metastatic lymph nodes and its significance in radiotherapy planning in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys, 2010 Mar 15;76(4):1127-32. Epub 2009 Aug 3.

Ghadjar P, Simcock M, Schreiber-Facklam H, Zimmer Y, Gräter R, Evers C, Arnold A, Wilkens L, Aebersold DM. Incidence of Small Lymph Node Metastases With Evidence of Extracapsular Extension: Clinical Implications in Patients With Head and Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2010 Dec 1;78 (5): 1366-72. Epub 2010 Mar 16.

Rothschild S, Bucher SE, Bernier J, Aebersold DM, Zouhair A, Ries G, Lombrieser N, Lippuner T, Lütolf UM, Glanzmann C, Ciernik IF (2010) Gefitinib in Combination with Irradiation with or Without Cisplatin in Patients with Inoperable Stage III Non-Small Cell Lung Cancer: A Phase I Trial. Int J Radiat Oncol Biol Phys. 2011 May 1;80 (1): 126-32. Epub 2010 Jun 18.

Zimmer Y, Vaseva AV, Medová M, Streit B, Blank-Liss W, Greiner RH, Schiering N, Aebersold DM (2010) Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274. Cancer Lett. 2010 Mar 28;289(2):228-36. Epub 2009 Sep 23.

Medova M, Aebersold DM, Blank-Liss W, Streit B, Medo M, Aebi S, Zimmer Y (2010) MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest. Genes Cancer. 2010 Oct; 1 (10): 1053-62.

Ghadjar P, Gwerder N, Manser P, Vock J, Madlung A, Mini R, Aebersold DM (2010) High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer. Strahlenther Onkol. 2010 Dec; 186(12):687-92. Epub 2010 Nov 30.

Ghadjar P, Rentsch CA, Isaak B, Behrensmeier F, Thalmann GN, Aebersold DM (2011) Urethral toxicity vs. cancer control-lessons to be learned from high-dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. Brachytherapy. 2011 Jul-Aug; 10(4):286-94. Epub 2010 Oct 28.

Ghadjar P, Simcock M, Studer G, Allal AS, Ozsahin M, Bernier J, Töpfer M, Zimmermann F, Betz M, Glanzmann C, Aebersold DM; on behalf of the Swiss Group for Clinical Cancer Research (SAKK) (2011)

Concomitant Cisplatin and Hyperfractionated Radiotherapy in Locally Advanced Head and Neck Cancer: 10-Year Follow-up of a Randomized Phase III Trial (SAKK 10/94). Int. J Radiat Oncol Biol Phys. 2011 Feb 16. [Epub ahead of print].

Medova M, Aebersold DM, Zimmer Y (2011) MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks. Int J Cancer. 2012 Feb 1;130(3):728-34. doi: 10.1002/ijc.26058. Epub 2011 May 9.

Ghadjar P, Kaanders JH, Poortmans P, Zaucha R, Krengli M, Lagrange JL, Ozsoy O, Nguyen TD, Miralbell R, Baize A, Boujelbene N, Collen T, Scandolaro L, Untereiner M, Goldberg H, Pesce GA, Anacak Y, Friedrich EE, Aebersold DM, Beer KT (2011) The Essential Role of Radiotherapy in the Treatment of Merkel Cell Carcinoma: A Study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e583-91. Epub 2011 Jul 19.

Ghadjar P, Bojaxhiu B, Simcock M, Terribilini D, Isaak B, Gut P, Wolfensberger P, Brömme JO, Geretschläger A, Behrensmeier F, Pica A, Aebersold DM. High Dose-Rate Versus Low Dose-Rate Brachytherapy for Lip Cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 16. [Epub ahead of print].